Drug Profile


Alternative Names: M118

Latest Information Update: 29 Jul 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Momenta Pharmaceuticals
  • Class Antithrombotics; Low molecular weight heparins
  • Mechanism of Action Antithrombin III inhibitors; Factor Xa inhibitors; Thrombin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute coronary syndromes

Most Recent Events

  • 10 Mar 2011 Adomiparin is available for partnering (http://
  • 02 Nov 2010 Momenta Pharmaceuticals receives a Qualifying Therapeutic Discovery Project grant from the US Government for M 118 development in Acute coronary syndromes
  • 24 Sep 2009 Efficacy and adverse events data from the phase IIa EMINENCE trial released by Momenta Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top